Items where authors include "Baraliakos, X"

Article

De Marco, G orcid.org/0000-0003-2406-161X, Zabotti, A, Baraliakos, X et al. (7 more authors) (2023) Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open, 9 (2). e003143. ISSN 2056-5933

Zabotti, A, De Marco, G orcid.org/0000-0003-2406-161X, Gossec, L et al. (26 more authors) (2023) EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967

Gladman, DD, Mease, PJ, Bird, P et al. (14 more authors) (2022) Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials, 23 (1). 743. ISSN 1745-6215

Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, DD et al. (14 more authors) (2021) Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. The Lancet Rheumatology, 3 (10). e715-e723. ISSN 2665-9913

Coates, LC, Baraliakos, X, Blanco, FJ et al. (17 more authors) (2021) The phenotype of axial spondyloarthritis: is it dependent on HLA‐B27 status? Arthritis Care & Research, 73 (6). pp. 856-860. ISSN 2151-464X

Nash, P, Kerschbaumer, A, Dörner, T et al. (26 more authors) (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 80 (1). pp. 71-87. ISSN 0003-4967

Mandl, P, Ciechomska, A, Terslev, L et al. (7 more authors) (2019) Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR. RMD Open, 5 (2). e000950. ISSN 2056-5933

Braun, J, Baraliakos, X, Deodhar, A et al. (5 more authors) (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford, England), 58 (5). pp. 859-868. ISSN 1462-0324

Baraliakos, X, Conaghan, PG orcid.org/0000-0002-3478-5665, D'Agostino, M-A et al. (5 more authors) (2019) Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities. European Journal of Rheumatology, 6 (1). pp. 37-45. ISSN 2147-9720

Alunno, A, Carubbi, F, Stones, S orcid.org/0000-0002-5943-1310 et al. (3 more authors) (2018) The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. Frontiers in Medicine, 5. 290. ISSN 2296-858X

Baraliakos, X, Braun, J, Conaghan, P orcid.org/0000-0002-3478-5665 et al. (2 more authors) (2018) Update on imaging in rheumatic diseases. Clinical and experimental rheumatology, 36 (5 Suppl 114). p. 2. ISSN 0392-856X

Smolen, JS, Schöls, M, Braun, J et al. (34 more authors) (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77 (1). pp. 3-17. ISSN 0003-4967

Braun, J, Baraliakos, X, Deodhar, A et al. (8 more authors) (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases, 76 (6). pp. 1070-1077. ISSN 0003-4967

Lambert, RGW, Bakker, PAC, Van der Heijde, D et al. (19 more authors) (2016) Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 75 (11). pp. 1958-1963. ISSN 0003-4967

Baraliakos, X, Borah, B, Braun, J et al. (13 more authors) (2016) Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: An observational study. Annals of the Rheumatic Diseases, 75 (2). pp. 408-412. ISSN 0003-4967

Baeten, D, Sieper, J, Braun, J et al. (10 more authors) (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine, 373 (26). pp. 2534-2548. ISSN 0028-4793

Mandl, P, Navarro-Compan, V, Terslev, L et al. (19 more authors) (2015) EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Annals of the Rheumatic Diseases, 74 (7). pp. 1327-1339. ISSN 0003-4967

Conference or Workshop Item

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Zabotti, A, De Marco, G orcid.org/0000-0003-2406-161X, Gossec, L et al. (6 more authors) (2022) POS1079 CLINICAL CHARACTERIZATION OF PRODROMAL AND VERY EARLY PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW FOR THE DEFINITION OF CLINICAL AND IMAGING SUSPICIOUS FEATURES FOR PROGRESSION TO PSORIATIC ARTHRITIS. In: EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark.

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Behrens, F, Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Behrens, F, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Studies. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Behrens, F, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase-3, Randomized, Placebo-Controlled Studies. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (12 more authors) (2021) Efficacy of Guselkumab on Axial-Related Endpoints in Patients with Active Psoriatic Arthritis with Imaging-Confirmed Sacroiliitis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (15 more authors) (2020) Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies. In: 37º Congresso Brasileiro de Reumatologia, 19-22 Nov 2020, Virtual.

Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.